Prelude Therapeutics (PRLD) Total Liabilities (2019 - 2026)

Prelude Therapeutics has disclosed Total Liabilities across 8 years of filings, most recently posting $59.5 million for Q1 2026.

• Total Liabilities for Q1 2026 came in at $59.5 million, up 56.13% year-over-year; the trailing twelve-month figure through Mar 2026 was $59.5 million (up 56.13% YoY), and the FY2025 annual result was $72.7 million, up 64.97% from the prior year.
• Total Liabilities came in at $59.5 million for Q1 2026 at Prelude Therapeutics, down from $72.7 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $72.7 million in Q4 2025 to a low of $18.2 million in Q2 2022.
• The 5-year median for Total Liabilities is $36.4 million (2024), against an average of $35.2 million.
• Across the five-year window, Total Liabilities dropped 18.72% in 2023 and jumped 126.48% in 2024, its largest moves.
• Prelude Therapeutics' Total Liabilities stood at $25.1 million in 2022, then jumped by 61.89% to $40.6 million in 2023, then climbed by 8.58% to $44.1 million in 2024, then jumped by 64.97% to $72.7 million in 2025, then fell by 18.19% to $59.5 million in 2026.
• The last three Total Liabilities figures came in at $59.5 million (Q1 2026), $72.7 million (Q4 2025), and $36.2 million (Q3 2025), per Business Quant data.